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ABSTRACT 24 
Multiple sclerosis (MS) is an immune-mediated, inflammatory disease characterized by repeated 25 
episodes of demyelization. Objective: The present study aimed to trace the epidemiological 26 
and functional profile of patients with Multiple Sclerosis treated at a Reference Hospital in 27 
Manaus-AM. Method: 80 charts were selected for screening and subsequent application of the 28 
Functional Independence Measure (MIF) scale. Results: 32 patients were included in the study, 29 
23 females (74%), whose mean age was 35 (± 12) years, with a relationship between females 30 
and males of 2.5. The mean diagnostic time for men was 7.8 years and for women of 5.3 years. 31 
The mean score on the Total MIF scale was 110.9 (± 17.5). Conclusion: Epidemiological 32 
characteristics are in line with most similar studies, but lack further studies aimed at assessing 33 
the functionality of individuals with MS. 34 
 35 
Keywords: Multiple Sclerosis, Medical Records, Epidemiologic Studies 36 
 37 
RESUMO 38 
A esclerose múltipla (EM) é uma doença imuno-mediada, inflamatória, caracterizada por 39 
repetidos episódios de desmielinização. Objetivo: Traçar o perfil epidemiológico e funcional 40 
dos pacientes com Esclerose Múltipla atendidos em um Hospital de Referência de Manaus-AM. 41 
Método: Foram selecionados 80 prontuários para triagem e posterior aplicação da escala de 42 
Medida de Independência Funcional (MIF). Resultado: Foram incluídos no estudo 32 43 
pacientes, 23 do sexo feminino (74%) cuja média de idade era de 35 (± 12) anos verificando 44 
uma relação entre mulheres e homens de 2.5. O tempo de diagnóstico médio para os homens 45 
foi de 7.8 anos e para as mulheres de 5,3 anos. A média do escore na escala de MIF Total foi 46 
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de 110,9 (± 17,5). Conclusão: As características epidemiológicas estão em consonância com 47 
a maioria dos estudos semelhantes, mas carecem de mais estudos voltados para a avaliação 48 
da funcionalidade de indivíduos com EM.  49 
 50 
Palavras-chave: Esclerose Múltipla, Registros Médicos, Estudos Epidemiológicos 51 
  52 
INTRODUCTION 53 
 54 
Multiple sclerosis (MS) is an autoimmune, inflammatory, demyelinating and chronic disease that 55 
affects the central nervous system (CNS; It is more common in young adults and has an 56 
unknown etiology. Given the differences in prevalence rates among populations, the most 57 
accepted pathogenic hypothesis presumes that the development of MS is influenced by an 58 
interaction among factors related to genetics, infectious agents, and environment.1-4 The illness 59 
is characterized by demyelination episodes that lead to multiform clinical manifestations, which 60 
may be disabling, and functional deficits resulting from damage to parts of the neuraxis.5,6 61 
 62 
The incidence and prevalence of MS vary considerably around the world, presenting a 63 
significant relationship with ethnicity and geographical area.7,8 More recent studies have 64 
suggested that there are several regions in Brazil and Latin America where there are mixed-65 
race populations (European, African and Indian) that have developed over many generations.  66 
 67 
As a consequence, these areas show peculiar population-shaping characteristics and important 68 
ethnic differences, which lead to distinct regional prevalence’s of MS. A recent review defined 69 
five regional prevalence levels according to the number of affected people per 100,000 70 
inhabitants: very low for 0 to 13; low for 13 to 38; intermediate for 38 to 70; high for 70 to 170; 71 
and very high for 170 to 35.09,10  72 
 73 
In Brazil, the highest prevalence’s are reported in the South and Southeast regions, which 74 
suggests the existence of a South – North gradient. Even with this difference, the country is 75 
considered to have low prevalence of MS, with an average number of 15 affected people per 76 
100,000 inhabitants.11,12 77 
 78 
Because of diversity of symptoms and physiopathological processes, MS can vary in 79 
itssymptomatic presentation and follow an unpredictable, complex and heterogeneous clinical 80 
evolution.13,14  81 
 82 
Based on the decision of experts from the National Multiple Sclerosis Society in 1999, and 83 
according to clinical criteria characterized by progression or outbreak occurrence, the disease 84 
can be classified into several forms: relapsing-remitting (RRMS), primary progressive (PPMS), 85 
secondary progressive (SPMS) and progressive-relapsing (PRMS), as well as being categorized 86 
as benign or malignant.15 RRMS is the most common, and is characterized by clearly defined 87 
exacerbations, with complete recovery or permanent consequences and residual deficits. The 88 
other three types – PPMS, SPMS and PRMS – are marked by periods of progression of the 89 
disease.16-18 90 
 91 
It is known that, after an injury to the CNS, many symptoms may imply the development of long-92 
term consequences that can compromise the independent execution of functional activities; 93 
however, patients with the same disease and similar impairments may show different 94 
disabilities.19 The number of outbreaks, the time of evolution of the disease, the type of 95 
pyramidal impairments, and the presence of cerebellar or motor manifestations in the beginning 96 
of the condition are the main factors related to functional incapacity. 20 Because of the variety of 97 
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symptoms in MS, several assessment scales have been created to evaluate those who are 98 
affected. Kurtzke’s Expanded Disability Status Scale (EDSS) is the one that is best known and 99 
most used in clinical trials on MS, although the literature indicates that there are some limitations 100 
to this tool that require it to be complemented by the addition of functional scales.21,22 101 
 102 
Rehabilitation programs currently use the Functional Independence Measure (FIM) as a source 103 
of information in order to determine limitations, plan the best therapeutic approaches, and follow 104 
patients’ evolution.23,24 The FIM is one of the most common scales used to determine functional 105 
level in neurological patients. It has been applied to different diseases of the nervous system 106 
and in many age groups, and has been shown to be valid, sensitive and reliable.  107 
 108 
OBJECTIVE   109 
 110 
The aim of the present study was to describe the epidemiological and functional profile of 111 
patients diagnosed with MS who were admitted to the Demyelinating Diseases Service of 112 
Getúlio Vargas University Hospital, in Manaus, Amazonas.14 113 
 114 
METHODS 115 
 116 
This was a retrospective, cross-sectional and descriptive prospective study carried out with 117 
patients previously diagnosed with MS, utilizing data collected at the Demyelinating Diseases 118 
Service at Getúlio Vargas University Hospital, in Manaus, Amazonas.  119 
 120 
The participants were informed of the objectives and procedures of the study, and signed free 121 
and informed consent forms. This study was approved by the Research Ethics Committee of 122 
Federal University of Amazonas, under approval certificate CAE 61619716.8.0000.5020, and 123 
approval report 1.815.182. 124 
 125 
Data collection occurred in two stages, without restrictions as for age, site or extent of the lesion, 126 
origin and gender, and with participants who met the following inclusion criteria: having a definite 127 
diagnosis of MS, being within reach to be found and contacted, and being able to answer the 128 
FIM questionnaire.  129 
 130 
The first stage consisted of analyzing reports on patients admitted and diagnosed with MS 131 
between January 2010 and December 2015, with no restrictions regarding age, origin, gender, 132 
location or extension of the injury. In the second stage, this information was entered into forms 133 
with patients’ personal and clinical data.  134 
 135 
Patients were then identified, located, and contacted by phone in order to apply a functional 136 
assessment. The tool used to evaluate the disability of patients with restrictions was the 137 
Functional Independence Measure. The patients had to be able to answer simple questions or 138 
be accompanied by an acquaintance during the application of the questionnaire. 139 
 140 
Eighty medical records from patients identified during the first stage were analyzed; 48 were 141 
discarded, 20 because they did not have a definitive MS diagnosis and 28 because it was not 142 
possible to locate them to apply the FIM. Consequently, the sample for the study consisted of 143 
32 patients who met the inclusion criteria. 144 
 145 
The functional profile analysis was carried out by the FIM, which is a self-administered 146 
instrument to evaluate performance of motor and cognitive/social skills, and the assistance 147 
needed to carry out activities. The FIM includes 18 categories, each of which receives a score 148 
AC
CE
PT
ED
 M
AN
US
CR
IPT
Ac
t  
Fis
iat
r. 2
01
8;2
5(4
)
Souza LM, Oliveira ES, Sousa NAC, Arêas GPT, Arêas FZS. Epidemiological and functional profile of patients diagnosed with 
multiple sclerosis in Manaus, Amazonas. Acta Fisiatr. 2018;25(4). DOI: https://doi.org/10.11606/issn.2317-0190.v25i4a163863  
 
 Article in Press 
 
related to level of dependence: a score of 1 indicates total dependence and a score of 7 indicates 149 
total independence. The total score ranges from 18 to 126, and the lower the score, the more 150 
dependent the patient. The categories are grouped into six dimensions: 1) self-care (feeding, 151 
personal hygiene, bathing, dress upper half, dress lower half, use of the toilet); 2) sphincter 152 
control (control of urination and defecation); 3) transfers (bed, chair, wheelchair, toilet, bathroom, 153 
shower); 4) locomotion (gaits, wheelchair, stairs); 5) communication (understanding, 154 
expression); and 6) social cognition (social interaction, problem solving, memory).24 155 
 156 
In the present study, only the total FIM score and the mobility (minimum of 3 and maximum of 157 
21) and locomotion (minimum of 2 and maximum of 14) domains were assessed. An individual 158 
with no deficiencies reaches a score of 126, and a person showing total dependence gets a 159 
score of 18.25,26 160 
 161 
The data was expressed as average ± standard deviation. Initially, the Shapiro-Wilk normality 162 
test was used. The Student’s unpaired t-test was applied to analyze the difference between the 163 
normal means. The difference between several means was assessed through analysis of 164 
variance (ANOVA) and a post hoc Bonferroni test. The significance level was set at p<0.05. 165 
 166 
RESULTS  167 
 168 
Among the 32 patients included in the study, 29 were from Manaus and 3 lived in the countryside 169 
of the state of Amazonas. Twenty-three (74%) were females, with an average age of 35 ± 12 170 
years, and 9 (26%) were males, with an average age of 35 ± 11 years, a proportion of 2.5 women 171 
for each man.  172 
 173 
The patients’ ages varied from 12 to 60 years old; 46.8% were between 31 and 40 years old. 174 
The average time since diagnosis was 7.8 years for men and 5.3 years for women. The patients’ 175 
characteristics, shown in Table 1, did not present statistically significant differences; however, 176 
women were predominant in the sample.  177 
 178 
Table 1. Epidemiological characteristics of patients diagnosed with MS at the Demyelinating 179 
Diseases Service in Manaus, Amazonas, Brazil, between January 2010 and December 2015 180 
 181 
Variables N=32  
Men (n = 09) Women (n = 23) 
Proportion (%) 26% 74% 
Age group (years ±SD) 35 ± 11 35 ± 12 
Time since diagnosis (years) 7.8 5.3 
SD = standard deviation 182 
 183 
Table 2 exhibits comparative data with the average total FIM, mobility and locomotion scores 184 
and their standard deviation for gender, age group and time since diagnosis. Women presented 185 
higher average scores, and these values were statistically significant (p = 0.03) for both the total 186 
FIM score (115 ± 7) and the mobility score (20 ± 1). This showed that women had lower 187 
functional dependence when compared to men, whose average total FIM score was 100 ± 29, 188 
with a score of 17 ± 6 in the mobility domain. 189 
 190 
Table 2. Mean values for scores on the FIM. Total score and scores for mobility and locomotion 191 
domains for patients diagnosed with MS at the Demyelinating Diseases Service in Manaus, 192 
Amazonas, Brazil, between January 2010 and December 2015 193 
 194 
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Variables FIM 
(total) 
FIM 
(mobility) 
FIM 
(locomotion) 
 
Score +SD 
Sample (n=32) 110.9 ± 17.5 
  
Gender 
 
Female (n=23) 115 ± 7* 20 ± 1* 13 ± 1 
Male (n=9) 100 ± 29 17 ± 6 11 ± 4 
Age group (years) 
 
Less than 30(n =09) 110 ± 17 19 ± 2 13 ± 2 
31 to 40 (n= 15) 115 ± 7 20 ± 0.7 13 ± 0.8 
More than 40 (n= 08) 103 ± 28 18 ± 6 11 ± 4 
Time since diagnosis (years) 
 
1 to 4 (n = 11) 115 ± 8 20 ± 0.9 13 ± 1 
5 to 9 (n = 16) 112 ± 12 20 ± 2 13 ± 1 
10 or more (n = 05) 94 ± 33 16 ± 7 10 ± 5 
*p=0.03; SD = standard deviation 195 
 196 
Regarding the functional profile of the sample, the comparison of average total FIM scores 197 
among the variables revealed that most of these patients got scores near the maximum value 198 
(126 points); it was observed that these people had the capacity to perform their activities and 199 
needed little assistance. There was no statistical significance for age group and time since 200 
diagnosis among the patients in any of the three FIM categories, but the lowest average values 201 
were found for patients aged more than 40 years old with a time since diagnosis of 10 years or 202 
more. This result points to the hypothesis that older patients with more time since diagnosis 203 
present a functionally more dependent profile when compared to people who do not present 204 
these characteristics. 205 
 206 
DISCUSSION 207 
 208 
In the North region of Brazil, including the city of Manaus, there are few studies focused on the 209 
clinical and epidemiological aspects of MS, let alone its prevalence and incidence. The present 210 
study provides information at one point in time for a specialized public service in Manaus that is 211 
considered a reference center for demyelinating diseases. As such, it provides a situational 212 
diagnosis of the epidemiology and functionality of people with MS.  213 
 214 
Analysis of the epidemiological data shows a predominance of MS cases in females (74%). This 215 
is in accordance with an experiment carried out in Uberaba, Minas Gerais by Ribeiro et al.27 who 216 
observed a predominance of women (71.4%) in a sample similar in number (35 patients) to the 217 
one described in the present paper (35 patients). Ferreira et al.12 Negreiros et al.28 and Cardoso 218 
et al.6 also obtained comparable results regarding gender predominance in cities in 219 
Pernambuco, Paraíba and São Paulo, respectively, confirming a higher propensity of women 220 
for developing MS. As for average age, the findings of the present study were consistent with 221 
most of the literature for both genders, corroborating the fact that MS affects mainly young 222 
adults. 223 
 224 
Several instruments have been used to assess functional skills in patients with MS. Most studies 225 
describe the use of Kurtzke’s Expanded Disability Status Scale (EDSS); however, because of 226 
its limitations, researchers tend to complement it with other functional scales.21,22 In the present 227 
study, the authors opted for the FIM instrument, which was developed as an assessment tool 228 
that can be used to measure the current functional level of patients. The drawback of its use is 229 
the difficulty of comparing its results with the findings of other studies. 230 
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To evaluate the functionality of patients, cutoff values for analysis of the total FIM scores were 231 
based on those used by Riberto et al.24 The following score intervals were chosen: 18, complete 232 
dependence (total assistance); 19 – 60, modified dependence (assistance of up to 50% in an 233 
activity); 61 – 103, modified dependence (assistance of up to 25% in an activity); 104 – 126, 234 
complete/modified independence. Hence, the lower the score, the higher the level of 235 
dependence. 236 
 237 
The average total FIM score of 110.9 ± 17.5 showed a population characterized by 238 
complete/modified independence. Gender analysis, however, showed that female patients were 239 
mainly responsible for this result, with an average score of 115 ± 7; the male patients obtained 240 
an average score of 100 ± 29, which puts them at the level of modified dependence, needing up 241 
to 25% of assistance to complete an activity. According to a study by Tremlett et al.17 in which 242 
the female participants showed a 30% lower risk of obtaining low scores in the EDSS scale, 243 
even although MS is more frequent in females, the worst prognoses of long-term incapacity 244 
were made for affected men. Nevertheless, this conclusion still needs deeper analysis, and new 245 
investigations focused on the functional state of patients need to be carried out.14,23,24 246 
 247 
Regarding age group, patients more than 40 years old and with a time since diagnosis of more 248 
than ten years were categorized as requiring modified dependence and assistance of 25%, 249 
unlike younger patients, who showed complete/modified independence, as well as those 250 
diagnosed between 1 and 4 years ago. This finding suggests that age and time since diagnosis 251 
may interfere with clinical progression for these patients, particularly level of dependence. 252 
However, in order to confirm this hypothesis, other clinical factors of the disease need to be 253 
investigated.  254 
 255 
A systematic review by Vasconcelos et al.29 shows that there are prognostic aspects associated 256 
with demographic and clinical characteristics directly related to the progression of MS, and 257 
consequently, to functional performance, that are not limited to the data collected in the present 258 
study. The prognostic factors that are more commonly addressed and associated with clinical 259 
progression are, in addition to gender: the outbreak frequency in the first years of the disease; 260 
the residual deficit after the initial outbreak; the time interval between the first two outbreaks; 261 
and ethnicity.  262 
 263 
This set of information is paramount for accurately characterizing samples, given that MS is an 264 
illness with fluctuating clinical features and has stability phases that determine the impairment 265 
of patients’ capacities. This applies to recent research about MS in Brazil: Several studies have 266 
described the sociodemographic and epidemiological characteristics of patients with MS, but 267 
lack assessment of their functionality in addition to their clinical condition. That is why the 268 
analyses in the present study are based more on clinical reasoning in comparison with other 269 
research. 270 
 271 
As for clinical and demographic information, the present study revealed a few limitations during 272 
data collection. Nonetheless, it is hoped that it will contribute to unveiling the reality of MS in 273 
Manaus, Amazonas and the North region, so that the disease can be better mapped through 274 
incidence and prevalence studies in the near future. Also, since the study is based on data from 275 
a single public service, it does not reflect the situation of the state or the region. However, the 276 
objective of the present investigation was to describe the epidemiological and functional features 277 
of patients with MS from Manaus, where there is a center of reference for the treatment of this 278 
condition that admits patients from the entire state.  279 
 280 
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Hence, it is hoped that the study will encourage researchers to carry out more epidemiological 281 
and clinical studies on MS that allow assessment of the functional state of patients in other 282 
regions of the country, especially in states in the region, an area that lacks investigation of this 283 
topic.  284 
  285 
ACKNOWLEDGMENTS 286 
The authors would like to express their gratitude to everyone who provided assistance in this 287 
research. Special thanks go to the staff of the Demyelinating Diseases Service for providing a 288 
favorable environment during data collection. 289 
 290 
REFERENCES 291 
 292 
1. Compston A. Esclerosis multiple. In: Brostoff J, Scadding GK, Male DK, Roitt IM (eds). 293 
Inmunología clínica. London: Gower Med; 1994:9.2-9.7. 294 
 295 
2. Hillert J. Human leukocyte antigen studies in multiple sclerosis. Ann Neurol. 1994;36 296 
Suppl:S15-7. DOI: https://doi.org/10.1002/ana.410360706  297 
 298 
3. Poser CM, Brinar VV. The accuracy of prevalence rates of multiple sclerosis: a critical 299 
review. Neuroepidemiology. 2007;29(3-4):150-5. DOI: https://doi.org/10.1159/000111576  300 
 301 
4. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl 302 
J Med. 2000;343(13):938-52. DOI: https://doi.org/10.1056/NEJM200009283431307  303 
 304 
5. Kurtzke JF, Beebe GW, Nagler B, Auth TL, Kurland LT, Nefzger MD. Studies on the natural 305 
history of multiple sclerosis. 6. Clinical and laboratory findings at first diagnosis. Acta 306 
Neurol Scand. 1972;48(1):19-46. DOI: https://doi.org/10.1111/j.1600-307 
0404.1972.tb07525.x  308 
 309 
6. Cardoso E, Fukuda T, Pereira J, Seixas J, Miranda R, Rodrigues B, et al. Clinical and 310 
epidemiological profile of multiple sclerosis in a reference center in the State of Bahia, 311 
Brazil. Arq Neuropsiquiatr. 2006;64(3B):727-30. DOI: https://doi.org/10.1590/s0004-312 
282x2006000500005  313 
 314 
7. Cristiano E, Rojas J, Romano M, Frider N, Machnicki G, Giunta D, et al. The epidemiology 315 
of multiple sclerosis in Latin America and the Caribbean: a systematic review. Mult Scler. 316 
2013;19(7):844-54. DOI: https://doi.org/10.1177/1352458512462918  317 
 318 
8. Grzesiuk AK. Características clínicas e epidemiológicas de 20 pacientes portadores de 319 
esclerose múltipla acompanhados em Cuiabá - Mato Grosso. Arq Neuropsiquiatr. 320 
2006;64(3A):635-8. DOI: http://dx.doi.org/10.1590/S0004-282X2006000400022  321 
 322 
9. Brum DG, Barreira AA, Louzada-Junior P, Mendes-Junior CT, Donadi EA. Association of 323 
the HLA-DRB1*15 allele group and the DRB1*1501 and DRB1*1503 alleles with multiple 324 
sclerosis in White and Mulatto samples from Brazil. J Neuroimmunol. 2007;189(1-2):118-325 
24. DOI: https://doi.org/10.1016/j.jneuroim.2007.06.009  326 
 327 
10. Risco J, Maldonado H, Luna L, Osada J, Ruiz P, Juarez A, et al. Latitudinal prevalence 328 
gradient of multiple sclerosis in Latin America. Mult Scler. 2011;17(9):1055-9. DOI: 329 
https://doi.org/10.1177/1352458511405562  330 
 331 
AC
CE
PT
ED
 M
AN
US
CR
IPT
Ac
ta 
Fis
iat
r  2
01
8;2
5(4
)
Souza LM, Oliveira ES, Sousa NAC, Arêas GPT, Arêas FZS. Epidemiological and functional profile of patients diagnosed with 
multiple sclerosis in Manaus, Amazonas. Acta Fisiatr. 2018;25(4). DOI: https://doi.org/10.11606/issn.2317-0190.v25i4a163863  
 
 Article in Press 
 
11. Brasil. Ministério da Saúde. Portaria n. 391, de 5 de maio de 2015. Aprova o protocolo 332 
clínico e diretrizes terapêuticas da esclerose múltipla. Diário Oficial da República 333 
Federativa do Brasil, Brasília (DF); 2015 Maio 06, Seção 1: 40. 334 
 335 
12. Ferreira ML, Machado MI, Vilela ML, Guedes MJ, Ataíde L Jr, Santos S, et al. 336 
Epidemiologia de 118 casos de esclerose múltipla com seguimento de 15 anos no centro 337 
de referência do Hospital da Restauração de Pernambuco. Arq Neuropsiquiatr. 338 
2004;62(4):1027-32. DOI: http://dx.doi.org/10.1590/S0004-282X2004000600018  339 
 340 
13. Nessler S, Brück W. Advances in multiple sclerosis research in 2009. J Neurol. 341 
2010;257(9):1590-3. DOI: https://doi.org/10.1007/s00415-010-5689-y  342 
 343 
14. Kantarci OH, Pirko I, Rodriguez M. Novel immunomodulatory approaches for the 344 
management of multiple sclerosis. Clin Pharmacol Ther. 2014;95(1):32-44. DOI: 345 
https://doi.org/10.1038/clpt.2013.196  346 
 347 
15. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an 348 
international survey. National Multiple Sclerosis Society (USA) Advisory Committee on 349 
Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46(4):907-11. DOI: 350 
https://doi.org/10.1212/wnl.46.4.907  351 
 352 
16. Scalfari A, Neuhaus A, Daumer M, Muraro PA, Ebers GC. Onset of secondary progressive 353 
phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry. 354 
2014;85(1):67-75. DOI: https://doi.org/10.1136/jnnp-2012-304333  355 
 356 
17. Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y; UBC Neurologists. Impact of 357 
multiple sclerosis relapses on progression diminishes with time. Neurology. 358 
2009;73(20):1616-23. DOI: https://doi.org/10.1212/WNL.0b013e3181c1e44f  359 
 360 
18. Hammond SR, McLeod JG, Macaskill P, English DR. Multiple sclerosis in Australia: 361 
prognostic factors. J Clin Neurosci. 2000;7(1):16-9. DOI: 362 
https://doi.org/10.1054/jocn.1998.0107  363 
 364 
19. Verheyden G, Nieuwboer A, De Wit L, Thijs V, Dobbelaere J, Devos H, et al. Time course 365 
of trunk, arm, leg, and functional recovery after ischemic stroke. Neurorehabil Neural 366 
Repair. 2008;22(2):173-9. DOI: https://doi.org/10.1177/1545968307305456  367 
 368 
20. Oliveira EML, Annes M, Oliveira ASB, Gabbai AA. Esclerose múltipla: estudo clínico de 50 369 
pacientes acompanhados no Ambulatório de Neurologia UNIFESP-EPM. Arq 370 
Neuropsiquiatr. 1999;57(1):51-5. DOI: http://dx.doi.org/10.1590/S0004-371 
282X1999000100010  372 
 373 
21. Filippi M, Rocca MA. Multiple sclerosis: monitoring long-term treatments in multiple 374 
sclerosis. Nat Rev Neurol. 2010;6(8):421-2. DOI: https://doi.org/10.1038/nrneurol.2010.88  375 
 376 
22. Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Measuring the impact of MS 377 
on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology. 2003;60(1):31-378 
6. DOI: https://doi.org/10.1212/wnl.60.1.31  379 
 380 
23. Hsueh IP, Lin JH, Jeng JS, Hsieh CL. Comparison of the psychometric characteristics of 381 
the functional independence measure, 5 item Barthel index, and 10 item Barthel index in 382 
AC
CE
PT
ED
 M
AN
US
CR
IPT
Ac
ta 
Fis
iat
. 2
01
8;2
5(4
)
Souza LM, Oliveira ES, Sousa NAC, Arêas GPT, Arêas FZS. Epidemiological and functional profile of patients diagnosed with 
multiple sclerosis in Manaus, Amazonas. Acta Fisiatr. 2018;25(4). DOI: https://doi.org/10.11606/issn.2317-0190.v25i4a163863  
 
 Article in Press 
 
patients with stroke. J Neurol Neurosurg Psychiatry. 2002;73(2):188-90. DOI: 383 
https://doi.org/10.1136/jnnp.73.2.188  384 
 385 
24. Riberto M, Miyazaki MH, Jucá SSH, Sakamoto H, Pinto PPN, Battistella LR. Validação da 386 
Versão Brasileira da Medida de Independência Funcional. Acta Fisiatr. 2004;11(2):72-6. 387 
DOI: https://doi.org/10.5935/0104-7795.20040003  388 
 389 
25. Silva GA, Schoeller SD, Gelbcke FL, Carvalho ZMA, Silva EMJP. Avaliação funcional de 390 
pessoas com lesão medular: utilização da Escala de Independência Funcional – MIF. 391 
Texto Contexto Enferm. 2012;21(4):929-36. DOI: http://dx.doi.org/10.1590/S0104-392 
07072012000400025  393 
 394 
26. Pompeu SMAA, Moral CD, Pompeu JE, Yumi E. Perfil funcional dos pacientes atendidos 395 
no setor de fisioterapia neurológica do Promove São Camilo. Mundo Saúde: 2010; 34(2): 396 
218-24.  397 
 398 
27. Ribeiro SBF, Maia DF, Ribeiro JB, Cardoso FAG, Silva C. Clinical and epidemiological 399 
profile of patients with multiple sclerosis in Uberaba, Minas Gerais, Brazil. Arq 400 
Neuropsiquiatr 2011; 69(2A):184-7. DOI: http://dx.doi.org/10.1590/S0004-401 
282X2011000200008  402 
 403 
28. Negreiros AA, Sousa-Munõz RL, Oliveira BE, Nóbrega PV, Monteiro LL. Perfil clínico-404 
epidemiológico de pacientes com diagnóstico de esclerose múltipla na cidade de João 405 
Pessoa, Paraíba, Brasil. Arq Neuropsiquiatr. 2015;73(9):741-5. DOI: 406 
http://dx.doi.org/10.1590/0004-282X20150111  407 
 408 
29. Vasconcelos CCF, Damasceno A, Diniz DS, Figueira FFA. Critérios de progressão e 409 
falência terapêutica na Esclerose Múltipla. In: Frota ERC, Mendes MF, Vasconcelos CCF. 410 
Recomendações no tratamento da esclerose múltipla e neuromielite óptica. 2 ed. São 411 
Paulo: Omnifarma; 2016. p.185-216.  412 
AC
CE
PT
D M
AN
SC
RIP
T
Ac
ta 
Fis
iat
r. 2
01
8;2
5(4
)
